Survival analysis of HIV/AIDS in Anhui among different AIDS diagnosis and treatment guide-lines,2006-2022
Objective This study aims to compare the survival rates of HIV infected and AIDS patients(HIV/AIDS)in Anhui Province under different versions of Guidelines for Diagnosis and Treatment of AIDS,and explore the factors influencing survival time.Methods Based on a retrospective cohort study of HIV/AIDS in Anhui Province from 2006 to 2022,the study period was divided into five phases according to the publication dates of the Guidelines.The Life-table method and Cox proportional hazards model were used to analyze survival rates and factors influencing survival time.Results A total of 25 334 participants were included,of whom 83.51％were male,68.76％were aged of diagnosis＞30-＜60 years,and 49.70％resided in northern Anhui Province.The one-year survival rates across the five periods(95％,95％,97％,97％,and 96％)showed significant differences(x2=46.180,P＜0.001).Similarly,the two-year survival rates for the first four periods(93％,94％,95％,and 95％)also exhibited significant differences(x2=17.103,P＜0.001).Cox proportional hazards regression analysis revealed the following factors influencing HIV/AIDS mortality risk,females had 0.654 times lower risk than males(95％CI:0.588-0.727,P＜0.001).Individuals aged over 60 years had 4.665 times higher risk compared to younger individuals(95％CI:3.930-5.539,P＜0.001).Unmar-ried individuals had 1.555 times higher risk than married individuals(95％CI:1.382-1.750,P＜0.001).Those with education above primary school had 0.756 times lower risk compared to those with primary education(95％CI:0.688-0.831,P＜0.001).Homosexual transmission was associated with 0.586 times lower risk than heterosexual transmission(95％CI:0.524-0.656,P＜0.001).Additional-ly,higher CD4+T lymphocyte(CD4)counts were associated with 0.385 times lower risk compared to lower counts(95％CI:0.329-0.451,P＜0.001).Conclusions With the updates to China's Guide-lines,the survival rate of HIV/AIDS has shown an upward trend.
Human immunodeficiency virusAntiretroviral therapySurvival analysis
万方数据
维普
